RecruitingObstructive Sleep Apnea
App-Based Optimization of Long-Term CPAP Adherence and Quality of Life
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to optimize the time of CPAP usage to at least 6 hours a night for 6 nights per week for people who have OSA with the help of a smartphone application called SmartWell24. This application aims to target CPAP adherence.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ In both trials of Aim 2, twenty adults (≥18 years) per trial will be recruited who are newly diagnosed with OSA and speak English.
- ✓ In both trials, we will purposely recruit samples balanced by biological sex and OSA severity (apnea hypopnea index: 5-14 vs. ≥ 15).
- ✓ Inclusion Criteria are the same for both Aim 2 trials; Adult patients from MCCSM sites who:
- ✓ Are diagnosed with OSA based on clinical diagnostic testing via laboratory or home-based sleep study;
- ✓ Own and have the functional and cognitive ability to use an Apple (iOS9 or higher) or Android (4.2 or higher) smartphone with minimal to no assistance;
- ✓ Are prescribed continuous or auto-titrated CPAP;
- ✓ Agree to using a smartphone application and wearable wrist sensor; and
- ✓ Speak and read English.
You may not qualify if…
- ✕ Unwilling to complete study measures and engage with SleepWell24;
- ✕ Refuse to not use the Fitbit application during the study trial;
- ✕ Have any conditions that would impede full participation (e.g., communication or cognitive impairments that limit ability to read and/or follow directions, other acute or severe health, cognitive, or psychological conditions);
- ✕ Currently participating in other lifestyle programs (e.g. active, formal weight loss program or research study; smoking cessation program, etc.);
- ✕ Decide to use a different PAP device than ResMed Airsense 10;
- ✕ Prescribed high-dose benzodiazepines (equivalent to \> 1 mg lorazapam/night);
- ✕ Daily opioid medication use at night;'
- ✕ Unwilling to discontinue use of any current wearable sensor for the duration of the trial;
Where it's recruiting
Source: ClinicalTrials.gov · NCT06381115 · last updated 2025-12-30